Concepts (109)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Juvenile | 12 | 2022 | 32 | 3.690 |
Why?
|
| Rheumatology | 6 | 2022 | 29 | 1.520 |
Why?
|
| Fibromyalgia | 2 | 2022 | 14 | 1.400 |
Why?
|
| Autoimmune Diseases | 2 | 2019 | 241 | 1.210 |
Why?
|
| Lupus Erythematosus, Systemic | 4 | 2022 | 206 | 1.080 |
Why?
|
| Antirheumatic Agents | 5 | 2022 | 54 | 0.930 |
Why?
|
| Pediatrics | 2 | 2019 | 344 | 0.910 |
Why?
|
| Pharmaceutical Services | 1 | 2022 | 9 | 0.870 |
Why?
|
| Hereditary Autoinflammatory Diseases | 1 | 2022 | 3 | 0.850 |
Why?
|
| Uveitis | 4 | 2022 | 29 | 0.830 |
Why?
|
| Child | 15 | 2023 | 6928 | 0.820 |
Why?
|
| Chronic Pain | 1 | 2022 | 145 | 0.730 |
Why?
|
| Biological Products | 1 | 2022 | 143 | 0.710 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2019 | 22 | 0.700 |
Why?
|
| Sjogren's Syndrome | 1 | 2019 | 30 | 0.690 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2019 | 46 | 0.690 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2017 | 18 | 0.610 |
Why?
|
| Adolescent | 12 | 2022 | 8984 | 0.610 |
Why?
|
| Temporomandibular Joint Disorders | 2 | 2022 | 19 | 0.420 |
Why?
|
| Humans | 25 | 2023 | 86678 | 0.370 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 372 | 0.300 |
Why?
|
| Ovarian Cysts | 1 | 2005 | 17 | 0.280 |
Why?
|
| Femoral Neoplasms | 1 | 2005 | 24 | 0.270 |
Why?
|
| Teratoma | 1 | 2005 | 50 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2005 | 100 | 0.260 |
Why?
|
| Antibodies, Antinuclear | 2 | 2015 | 83 | 0.260 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2015 | 316 | 0.250 |
Why?
|
| Abdominal Pain | 1 | 2005 | 137 | 0.250 |
Why?
|
| Osteosarcoma | 1 | 2005 | 158 | 0.250 |
Why?
|
| Glucocorticoids | 4 | 2022 | 352 | 0.240 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2023 | 49 | 0.220 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 67 | 0.220 |
Why?
|
| Mycophenolic Acid | 1 | 2022 | 87 | 0.210 |
Why?
|
| Symptom Assessment | 1 | 2022 | 65 | 0.210 |
Why?
|
| Antibodies, Viral | 1 | 2023 | 293 | 0.200 |
Why?
|
| Pain Measurement | 1 | 2022 | 321 | 0.190 |
Why?
|
| Withholding Treatment | 2 | 2019 | 112 | 0.190 |
Why?
|
| Medication Adherence | 1 | 2022 | 129 | 0.190 |
Why?
|
| Dermatomyositis | 1 | 2020 | 17 | 0.190 |
Why?
|
| Myocarditis | 1 | 2020 | 51 | 0.180 |
Why?
|
| Parotid Gland | 1 | 2019 | 31 | 0.170 |
Why?
|
| S100A12 Protein | 1 | 2019 | 10 | 0.170 |
Why?
|
| Calgranulin A | 1 | 2019 | 11 | 0.170 |
Why?
|
| Ovarian Neoplasms | 1 | 2005 | 744 | 0.170 |
Why?
|
| Calgranulin B | 1 | 2019 | 16 | 0.170 |
Why?
|
| Depression | 1 | 2022 | 473 | 0.170 |
Why?
|
| Early Diagnosis | 1 | 2019 | 132 | 0.170 |
Why?
|
| United States | 6 | 2022 | 6681 | 0.160 |
Why?
|
| Autoantibodies | 1 | 2019 | 267 | 0.160 |
Why?
|
| Cytokines | 1 | 2022 | 778 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 147 | 0.150 |
Why?
|
| Quality of Life | 5 | 2022 | 1585 | 0.150 |
Why?
|
| Atrial Fibrillation | 1 | 2020 | 288 | 0.140 |
Why?
|
| Inflammation | 1 | 2022 | 923 | 0.140 |
Why?
|
| Risk Factors | 4 | 2023 | 5420 | 0.130 |
Why?
|
| Takayasu Arteritis | 1 | 2015 | 4 | 0.130 |
Why?
|
| Musculoskeletal Pain | 1 | 2015 | 10 | 0.130 |
Why?
|
| Calcitonin | 1 | 2014 | 38 | 0.130 |
Why?
|
| Diphosphonates | 1 | 2014 | 36 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 2504 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 977 | 0.120 |
Why?
|
| Young Adult | 2 | 2022 | 5980 | 0.120 |
Why?
|
| Bone Density | 1 | 2014 | 209 | 0.110 |
Why?
|
| Osteoporosis | 1 | 2014 | 121 | 0.110 |
Why?
|
| Temporomandibular Joint | 2 | 2022 | 20 | 0.110 |
Why?
|
| Vitamin D | 1 | 2014 | 261 | 0.100 |
Why?
|
| Immunization | 2 | 2022 | 158 | 0.100 |
Why?
|
| Male | 6 | 2023 | 40988 | 0.100 |
Why?
|
| Female | 8 | 2023 | 44550 | 0.100 |
Why?
|
| Urban Population | 1 | 2012 | 214 | 0.100 |
Why?
|
| Symptom Flare Up | 2 | 2019 | 11 | 0.080 |
Why?
|
| Torsion Abnormality | 1 | 2005 | 17 | 0.070 |
Why?
|
| Mucositis | 1 | 2005 | 17 | 0.070 |
Why?
|
| Infarction | 1 | 2005 | 26 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2005 | 81 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 114 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2019 | 683 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2005 | 295 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2005 | 1686 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 148 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2019 | 3613 | 0.050 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2022 | 166 | 0.050 |
Why?
|
| Anxiety | 1 | 2022 | 287 | 0.050 |
Why?
|
| Pain | 1 | 2022 | 391 | 0.050 |
Why?
|
| Hemodynamics | 1 | 2023 | 711 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 5214 | 0.040 |
Why?
|
| Disease Progression | 1 | 2023 | 1532 | 0.040 |
Why?
|
| Life Tables | 1 | 2018 | 48 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 336 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2020 | 478 | 0.040 |
Why?
|
| Echocardiography | 1 | 2023 | 911 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2020 | 840 | 0.040 |
Why?
|
| Registries | 1 | 2020 | 703 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 895 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2019 | 7998 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 860 | 0.030 |
Why?
|
| Arthralgia | 1 | 2015 | 36 | 0.030 |
Why?
|
| Knee Joint | 1 | 2015 | 168 | 0.030 |
Why?
|
| Bone Density Conservation Agents | 1 | 2014 | 45 | 0.030 |
Why?
|
| Absorptiometry, Photon | 1 | 2014 | 99 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2014 | 278 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2014 | 154 | 0.030 |
Why?
|
| Adult | 2 | 2022 | 25659 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 1718 | 0.030 |
Why?
|
| Infant | 1 | 2018 | 3047 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 8496 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2018 | 4214 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1621 | 0.020 |
Why?
|